BR112023004271A2 - Composições de ativação de sting polivalentes e usos das mesmas - Google Patents
Composições de ativação de sting polivalentes e usos das mesmasInfo
- Publication number
- BR112023004271A2 BR112023004271A2 BR112023004271A BR112023004271A BR112023004271A2 BR 112023004271 A2 BR112023004271 A2 BR 112023004271A2 BR 112023004271 A BR112023004271 A BR 112023004271A BR 112023004271 A BR112023004271 A BR 112023004271A BR 112023004271 A2 BR112023004271 A2 BR 112023004271A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- multipurpose
- sting
- treatment
- sting activation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000004913 activation Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940044665 STING agonist Drugs 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075560P | 2020-09-08 | 2020-09-08 | |
| PCT/US2021/049365 WO2022055929A1 (en) | 2020-09-08 | 2021-09-08 | Polyvalent sting activating compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004271A2 true BR112023004271A2 (pt) | 2023-04-04 |
Family
ID=80469374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004271A BR112023004271A2 (pt) | 2020-09-08 | 2021-09-08 | Composições de ativação de sting polivalentes e usos das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12036319B2 (https=) |
| EP (1) | EP4210707A4 (https=) |
| JP (1) | JP2023546316A (https=) |
| KR (1) | KR20230066019A (https=) |
| CN (1) | CN116490193A (https=) |
| AU (1) | AU2021340623A1 (https=) |
| BR (1) | BR112023004271A2 (https=) |
| CA (1) | CA3191593A1 (https=) |
| IL (1) | IL301190A (https=) |
| MX (1) | MX2023002797A (https=) |
| WO (1) | WO2022055929A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805309A (zh) * | 2022-06-07 | 2022-07-29 | 中国药科大学 | 苯并杂环类化合物及其制备方法、药物组合物和应用 |
| CN117599199B (zh) * | 2023-11-20 | 2025-03-04 | 北京大学 | 用于靶蛋白水解的聚合物及其制备方法和用途 |
| CN120242033B (zh) * | 2025-06-03 | 2025-08-22 | 合肥市第一人民医院 | 一种纳米组装体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934598B1 (en) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| US20180344758A1 (en) | 2014-12-17 | 2018-12-06 | Lipogen Llc | Method of Treating Cancer with cGAMP or cGAsMP |
| CA3016457A1 (en) * | 2016-03-02 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| EP3691640A1 (en) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Methods for administering sting agonists |
| WO2019161171A1 (en) | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
| US11096899B2 (en) * | 2018-09-07 | 2021-08-24 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
| JP7676331B2 (ja) * | 2019-06-22 | 2025-05-14 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 生分解性超ｐＨ感受性ポリマー |
-
2021
- 2021-09-08 AU AU2021340623A patent/AU2021340623A1/en active Pending
- 2021-09-08 JP JP2023515254A patent/JP2023546316A/ja active Pending
- 2021-09-08 BR BR112023004271A patent/BR112023004271A2/pt unknown
- 2021-09-08 CN CN202180071894.1A patent/CN116490193A/zh active Pending
- 2021-09-08 EP EP21867478.6A patent/EP4210707A4/en active Pending
- 2021-09-08 MX MX2023002797A patent/MX2023002797A/es unknown
- 2021-09-08 US US17/469,111 patent/US12036319B2/en active Active
- 2021-09-08 IL IL301190A patent/IL301190A/en unknown
- 2021-09-08 WO PCT/US2021/049365 patent/WO2022055929A1/en not_active Ceased
- 2021-09-08 CA CA3191593A patent/CA3191593A1/en active Pending
- 2021-09-08 KR KR1020237010998A patent/KR20230066019A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3191593A1 (en) | 2022-03-17 |
| CN116490193A (zh) | 2023-07-25 |
| IL301190A (en) | 2023-05-01 |
| JP2023546316A (ja) | 2023-11-02 |
| AU2021340623A1 (en) | 2023-04-13 |
| WO2022055929A1 (en) | 2022-03-17 |
| EP4210707A4 (en) | 2024-10-16 |
| MX2023002797A (es) | 2023-05-04 |
| US20220071903A1 (en) | 2022-03-10 |
| KR20230066019A (ko) | 2023-05-12 |
| EP4210707A1 (en) | 2023-07-19 |
| US12036319B2 (en) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023004271A2 (pt) | Composições de ativação de sting polivalentes e usos das mesmas | |
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| CO2023018231A2 (es) | Restos de administración terapéutica novedosos y usos de estos | |
| MX390894B (es) | Polipéptido de fusión anti-cáncer. | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112022002599A2 (pt) | Vesícula extracelular ligada a moléculas e usos da mesma | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| PE20151180A1 (es) | Anticuerpos anti-ceacam5 y usos de estos | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
| MX2017012982A (es) | Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores. | |
| CY1116344T1 (el) | Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| BR112016015818A2 (pt) | Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1 | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| BR112015006176A8 (pt) | método de tratamento de câncer em um indivíduo com necessidade de tratamento | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| BR112022003633A2 (pt) | Métodos para produção de arginase 1 recombinante humana e usos da mesma | |
| WO2017180789A8 (en) | Methods of treatment using chlorotoxin conjugates | |
| MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
| JOP20200242A1 (ar) | مركبات البلاديينوليد واستخداماتها | |
| CR20210161A (es) | Composiciones farmacéuticas semisólidas de base oleosa conteniendo pirfenidona para su aplicación en la reparación tisular |